|
|
| | Dopamine D3 Receptor Agonist 13a Basic information |
| | Dopamine D3 Receptor Agonist 13a Chemical Properties |
| solubility | DMF: Soluble
Ethanol: 3 mg/ml |
| | Dopamine D3 Receptor Agonist 13a Usage And Synthesis |
| Uses | Dopamine D3 receptor ligand-5 (13a), a Cariprazine (HY-14763) analogue, is a dopamine D3 receptor ligand, with Ki values of 2.85 nM and 0.14 nM for D2R and D3R, respectively[1]. | | in vivo | Dopamine D3 receptor ligand-5 (13a) decreases cocaine self-administration (FR2; 1-10 mg/kg, i.p.) in rats, suggesting that partial agonists/antagonists with modest D3R/D2R-selectivity may be effective in treating PSUD and potentially comorbidities with other affective disorders[1]. | | IC 50 | D3 Receptor: 0.14 nM (Ki); 5-HT2B Receptor: 1.47 nM (Ki); D2 Receptor: 2.85 nM (Ki); 5-HT1A Receptor: 6 nM (Ki); 5-HT2A Receptor: 54 nM (Ki); 5-HT2C Receptor: 252 nM (Ki); D4 Receptor: 756 nM (Ki); D1 Receptor: 4600 nM (Ki) | | References | [1] Emma S Gogarnoiu, et al. Dopamine D3/D2 Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders. J Med Chem. 2023 Feb 9;66(3):1809-1834. DOI:10.1021/acs.jmedchem.2c01624 |
| | Dopamine D3 Receptor Agonist 13a Preparation Products And Raw materials |
|